What adverse effect may occur in a client with liver disease receiving promethazine for nausea?

The adverse effect of cholestatic jaundice in a client with liver disease receiving promethazine is significant due to the drug's potential hepatotoxicity and how it can exacerbate existing liver conditions. Promethazine is metabolized in the liver, and when liver function is compromised, the drug's clearance can be impaired, leading to increased blood levels of the drug and heightened risk for hepatic side effects. Cholestatic jaundice occurs when bile flow is obstructed, which can happen due to liver damage or dysfunction; promethazine, by adding additional strain to the liver, can lead to this condition manifesting in vulnerable patients.

This outcome highlights the importance of monitoring liver function in patients taking this medication, especially those already diagnosed with liver disorders, as they are at a greater risk of developing serious complications from drugs that are processed by the liver. The potential for cholestatic jaundice makes it crucial to assess and understand liver enzyme levels before initiating therapy with promethazine in individuals with liver disease to avoid exacerbating their condition.